This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Amevive

Astellas Pharma, Inc.

Drug Names(s): alefacept, recombinantly engineered LFA-1/IgG1 human fusion protein, ASP0485

Description: Amevive (human lymphocyte function-associated antigen 3 / immunoglobulin 1 fusion protein) is the first approved biological product for moderate-to-severe plaque psoriasis.

Preclinical studies show that Amevive modulates immune responses by binding to the CD2 receptor. This leads to inhibition of CD2 molecules on the surface of activated T cells, selectively targeting memory-effector (CD45RO+) T cells that comprise more than 75% of T cells in psoriatic plaques.

Deal Structure: Astellas Pharma no longer reports revenues for Amevive as of Q1 2012. Because of this, BMT is no longer forecasting revenues for this drug.

In April 2006, Astellas Pharma US and Biogen Idec announced an agreement for Astellas to purchase the worldwide rights to AMEVIVE. Under the terms of the agreement, Astellas would acquire the worldwide rights to AMEVIVE in all indications from Biogen Idec. Biogen Idec would continue to manufacture AMEVIVE and supply product to Astellas.

Partners: Biogen, Inc.


Amevive News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug